In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Icecure Medical (ICCM – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $1.01.
Vendetti covers the Healthcare sector, focusing on stocks such as Icecure Medical, Biolase, and Aethlon Medical. According to TipRanks, Vendetti has an average return of -3.2% and a 32.06% success rate on recommended stocks.
Icecure Medical has an analyst consensus of Strong Buy, with a price target consensus of $3.67, representing a 263.37% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
ICCM market cap is currently $51.83M and has a P/E ratio of -2.09.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Icecure Medical Ltd is a Israel based firm which develops and markets minimally invasive cryoablation therapies for women’s health. The company provides a minimally invasive, in-office definitive treatment for symptomatic breast fibroadenoma.
Read More on ICCM:
- IceCure Medical price target lowered to $4 from $4.25 at Alliance Global
- IceCure Medical Reports First Half 2023 Financial & Operational Results: Global Adoption of Cryoablation Technology Gaining Momentum
- IceCure Medical management to meet with Maxim
- IceCure Medical announces regulatory approval of ProSense System in Canada
- IceCure Medical enters distribution agreement with Medicinalia Cormedica
